drugset / Trial / NCT00348686

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

NCT00348686

Phase 4 Completed 315 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.

Timeline

Start
2006-06
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan Unknown 16 mg Oral
Subject Candesartan Unknown 32 mg Oral
Subject Felodipine Small molecule 5 mg Oral
Subject Felodipine Small molecule 10 mg Oral